» Traumatic brain injury preceding clinically diagnosed {alpha}-synucleinopathies: A case-control study
24/02/20 20:45 from Neurology current issue
Objective To determine the association between traumatic brain injury (TBI) and any clinically diagnosed α-synucleinopathy including Parkinson disease (PD), dementia with Lewy bodies (DLB), PD dementia (PDD), and multiple system at...

» Unique white matter structural connectivity in early-stage drug-naive Parkinson disease
24/02/20 20:45 from Neurology current issue
Objective To investigate the topographic arrangement and strength of whole-brain white matter (WM) structural connectivity in patients with early-stage drug-naive Parkinson disease (PD). Methods We employed a model-free data-driven appro...

» Real-space navigation testing differentiates between amyloid-positive and -negative aMCI
24/02/20 20:45 from Neurology current issue
Objective To distinguish between patients with amyloid-positive (A+) and -negative (A–) amnestic mild cognitive impairment (aMCI) by simultaneously investigating navigation performance, visual exploration behavior, and brain activa...

» Traumatic brain injury and {alpha}-synuclein: Proceed with caution
24/02/20 20:45 from Neurology current issue
Observational studies strongly suggest that environmental factors contribute to the development of Parkinson disease (PD). 1 These investigations have broadened our understanding of PD pathophysiology, helped guide therapeutic developmen...

» Casting a wide net to find the molar tooth: A study on Joubert syndrome
24/02/20 20:45 from Neurology current issue
Joubert syndrome is a genetically heterogeneous group of congenital ataxias that share a distinctive cerebellar and hindbrain malformation referred to in the literature as the molar tooth sign. 1,2 Based largely on unpublished data, the ...

» Amyotrophic lateral sclerosis on the scale: The weighting of fat
24/02/20 20:45 from Neurology current issue
Amyotrophic lateral sclerosis (ALS) remains one of the most intensely studied but elusive fatal neurologic conditions. Despite its low incidence, it has been extensively studied in prospective epidemiologic studies to define a risk profi...

» What's happening in Neurology(R) Clinical Practice
24/02/20 20:45 from Neurology current issue
Articles appearing in the April 2019 issue

» What's happening in Neurology(R) Neuroimmunology & Neuroinflammation
24/02/20 20:45 from Neurology current issue
Articles appearing in the July 2019 issue

» Posterior primary progressive prosopagnosia: Structural and molecular imaging
24/02/20 20:45 from Neurology current issue
Amyloid-negative pathology underlying primary progressive prosopagnosia usually affects the tip of the right temporal lobe first. 1,2 However, a 69-year-old right-handed man, with amyloid-negative PET imaging, had severe progressive pros...

» [Corrections] Correction to Lancet Neurol 2020; 19: 38–48
19/02/20 00:19 from The Lancet Neurology
Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol 202...

» [Corrections] Correction to Lancet Neurol 2020; 19: 247–54
19/02/20 00:19 from The Lancet Neurology
Hopfner F, Höglinger GU, Kuhlenbäumer G, et al. β-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurol 2020; 19: 247–54—In this Article, datapoints marked with an asterisk in figure 1A are now labelled as significant and da...

» [Correspondence] Patient-reported outcome measures: the need for new and reliable tools
19/02/20 00:19 from The Lancet Neurology
I read with great interest the Editorial on patient-reported outcomes for neurological diseases.1 Although traditional outcome measures, such as morbidity and mortality, are necessary, they are insufficient for comprehensive outcome asse...

» [Correspondence] Health-care disparities for people with multiple sclerosis
19/02/20 00:19 from The Lancet Neurology
The Lancet Neurology's December Editorial featured the Multiple Sclerosis International Federation application to add multiple sclerosis treatments to the WHO Essential Medicines List (EML).1 The WHO EML Expert Committee recognised the h...

» [Correspondence] Osmotherapy in traumatic brain injury
19/02/20 00:19 from The Lancet Neurology
Although mortality from traumatic brain injury (TBI) has decreased, a high proportion of TBI survivors still have long-term physical, cognitive, and psychological morbidity.1 There is a pressing need for further data on the long-term eff...

» Concussions Linked With Erectile Dysfunction in Football Player Study
18/02/20 00:00 from JAMA Current Issue
This Medical News article discusses a recent JAMA Neurology study that found an association between concussion symptoms and later indicators of erectile dysfunction and low testosterone in former National Football League players.

» One hundred years of shared interest
13/02/20 13:45 from Journal of Neurology, Neurosurgery & Psychiatry current issue
At a time of increasing specialisation in journal publishing it is remarkable that a journal combining neurology and psychiatry has stood the test of time. At the start of the 20th century, a number of international neurology journals su...

» Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis
13/02/20 13:45 from Journal of Neurology, Neurosurgery & Psychiatry current issue
Introduction The diagnosis of amyotrophic lateral sclerosis (ALS) requires recognition of both lower motor neuron (LMN) and upper motor neuron (UMN) dysfunction. 1 However, classical UMN signs are frequently difficult to identify in ALS....

» Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
13/02/20 13:45 from Journal of Neurology, Neurosurgery & Psychiatry current issue
Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential bioma...

» Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG
13/02/20 13:45 from Journal of Neurology, Neurosurgery & Psychiatry current issue
Introduction Purkinje cell cytoplasmic antibody type-2 (PCA2-IgG) was first defined as a paraneoplastic biomarker based on a unique immunofluorescence pattern seen on a mouse composite brain tissue assay. 1 Lung and breast cancer are the...

» Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimers disease
13/02/20 13:45 from Journal of Neurology, Neurosurgery & Psychiatry current issue
Introduction Subjective cognitive decline (SCD) has been implicated as an early marker of subtle cognitive change in preclinical Alzheimer’s disease (AD). 1 The relationship between SCD and molecular markers of disease progression ...

Powered by Feed Informer